GlobeImmune Inc. today presented safety and immunogenicity data from two clinical studies of therapeutic vaccines based on the Company's Tarmogen® technology. In the first study, GI-4000, a series of ...
Biodesix, Inc. announced initial results of their proteomic analysis of GlobeImmune’s Phase 2 adjuvant trial of GI-4000 plus gemcitabine (Gemzar; Lilly, Eli and Company) vs. gemcitabine alone in ras ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback